ArticleClinical and experimental medicine2025
Identification of DNA damage response and crotonylation-related biomarkers for lung adenocarcinoma via machine learning and WGCNA.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive analysis ofJournal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
DNA damage response (DDR) and crotonylation occur frequently in lung adenocarcinoma (LUAD), but their relationship is yet to be elucidated. RNA sequencing data from LUAD patients in GSE27262 and GSE140797 datasets were obtained. DDR-crotonylation-related differentially expressed genes were identified by differential analysis and weighted gene co-expression network analysis. Three machine learning algorithms were used to screen for foremost ones. Various analyses such as immune infiltration, genetic mutation, and drug sensitivity were carried out based on multiple databases and cytotoxicity tests. Three hub genes were extracted with the potential as diagnostic and predictive criteria. They were also related to immune infiltration, immune checkpoint expression and genome heterogeneity of LUAD. Additionally, drug sensitivity analysis pinpointed probable small molecule inhibitors targeting our hub genes. This study confirmed the activation of DDR and crotonylation in LUAD, which is characterized by abnormal expressions of the hub genes, and translated it into clinical applications. We also overviewed the relationships among those specific molecular features, metabolic reprogramming and immune evasion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.